Physiomics (AIM:PYC), the mathematical modelling, data science and biostatistics company, has created a hantavirus translational modelling framework demonstrating its quantitative pharmacology and mechanistic modelling capabilities in infectious disease applications.
The framework integrates multiple evidence layers, in vitro phenotypic antiviral screening, concentration-response potency modelling, human pharmacokinetic exposure translation, mechanistic PK/PD viral dynamics and virtual population simulations, into a single translational workflow.
Physiomics says the workflow is designed to assess whether antiviral activity observed in laboratory systems could plausibly translate into meaningful viral suppression under simulated human exposure conditions.
Illustrative components include simulated 384‑well antiviral screens, EC50/Emax concentration-response fitting, human PK exposure simulations against potency-linked targets, mechanistic viral-load dynamics across modalities and time‑to‑clearance virtual population runs.
"This framework demonstrates how Physiomics can integrate assay data, pharmacokinetics, viral dynamics and virtual population simulations into a coherent scientific workflow capable of supporting exposure‑response assessment and programme prioritisation," said Mike Whitlow, Executive Director of Physiomics plc.
The company cautioned the material is illustrative only, does not constitute evidence of clinical efficacy for any compound and has not yet had any commercial application.
It added that it will continue to explore additional infectious disease modelling frameworks and provide further updates as appropriate.
